These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 35001643)
1. Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial. Najib U; Smith T; Hindiyeh N; Saper J; Nye B; Ashina S; McClure CK; Marmura MJ; Chase S; Liebler E; Lipton RB Cephalalgia; 2022 Jun; 42(7):560-569. PubMed ID: 35001643 [TBL] [Abstract][Full Text] [Related]
2. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Diener HC; Goadsby PJ; Ashina M; Al-Karagholi MA; Sinclair A; Mitsikostas D; Magis D; Pozo-Rosich P; Irimia Sieira P; Làinez MJ; Gaul C; Silver N; Hoffmann J; Marin J; Liebler E; Ferrari MD Cephalalgia; 2019 Oct; 39(12):1475-1487. PubMed ID: 31522546 [TBL] [Abstract][Full Text] [Related]
3. Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. Martelletti P; Barbanti P; Grazzi L; Pierangeli G; Rainero I; Geppetti P; Ambrosini A; Sarchielli P; Tassorelli C; Liebler E; de Tommaso M; J Headache Pain; 2018 Nov; 19(1):101. PubMed ID: 30382909 [TBL] [Abstract][Full Text] [Related]
4. Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. Grazzi L; Tassorelli C; de Tommaso M; Pierangeli G; Martelletti P; Rainero I; Geppetti P; Ambrosini A; Sarchielli P; Liebler E; Barbanti P; J Headache Pain; 2018 Oct; 19(1):98. PubMed ID: 30340460 [TBL] [Abstract][Full Text] [Related]
5. Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial. Tepper SJ; Grosberg B; Daniel O; Kuruvilla DE; Vainstein G; Deutsch L; Sharon R Headache; 2022 Sep; 62(8):989-1001. PubMed ID: 35748757 [TBL] [Abstract][Full Text] [Related]
15. External Concurrent Occipital and Trigeminal Neurostimulation Relieves Migraine Headache: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial. Daniel O; Tepper SJ; Deutsch L; Sharon R Pain Ther; 2022 Sep; 11(3):907-922. PubMed ID: 35661128 [TBL] [Abstract][Full Text] [Related]
16. Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study. Silberstein SD; Mechtler LL; Kudrow DB; Calhoun AH; McClure C; Saper JR; Liebler EJ; Rubenstein Engel E; Tepper SJ; Headache; 2016 Sep; 56(8):1317-32. PubMed ID: 27593728 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial. Spierings ELH; Kärppä M; Ning X; Cohen JM; Campos VR; Yang R; Reuter U J Headache Pain; 2021 Apr; 22(1):26. PubMed ID: 33863272 [TBL] [Abstract][Full Text] [Related]
18. Vagus nerve stimulation for pediatric patients with intractable epilepsy between 3 and 6 years of age: study protocol for a double-blind, randomized control trial. Ji T; Yang Z; Liu Q; Liao J; Yin F; Chen Y; Zou L; Li B; Gao Y; Shu X; Huang S; Gao F; Liang J; Lin SF; Peng J; Song S; Wang J; Che C; Sun W; Tian M; Yang L; Hua Y; Hao Y; Cai L; Li L; Jiang Y Trials; 2019 Jan; 20(1):44. PubMed ID: 30642370 [TBL] [Abstract][Full Text] [Related]
19. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial. Lipton RB; Pozo-Rosich P; Blumenfeld AM; Dodick DW; McAllister P; Li Y; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM JAMA Netw Open; 2022 Jun; 5(6):e2215499. PubMed ID: 35675076 [TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]